Navigation Links
Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial

ts to develop and commercialize ISA247 for all transplant indications.

On September 30, 2005, Isotechnika Inc. entered into an exclusive worldwide licensing agreement with Atrium Medical Corporation for the use of ISA247 and TAFA93 specifically with drug eluting devices for the non-systemic treatment of vascular, cardiovascular, target vessel and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement on April 25, 2006, granting Isotechnika the option to obtain an exclusive license to develop and commercialize conjugates consisting of Cellgate's patented transporter technology for the topical delivery of ISA247 in patients suffering from mild to moderate psoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with Lux Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences worldwide rights to develop and commercialize Isotechnika's lead drug, ISA247 for the treatment and prophylaxis of all ophthalmic diseases.

Forward-Looking Statements

--------------------------

This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patent
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
(Date:10/30/2014)... Extensiv hydrolysierte Milch ... Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ist die ... Kleinkindern. Der bisher übliche Umgang mit dieser ... bzw. deren stillenden Mütter Milchproteine zu vermeiden. ... einer beträchtlichen Anzahl von Kindern der Aufbau ...
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3
... 2011 Aethlon Medical, Inc. (OTCBB: ... to address infectious disease and cancer, announces that ... a company overview, discuss recent developments and review ... & Medical Technologies Virtual Conference.   ...
... June 7, 2011 CMR Institute , the leading ... announces the addition of two new e-modules to help representatives ... (ACA): The Affordable Care ... Accountable Care Organizations and Future Healthcare Delivery ...
Cached Medicine Technology:Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16 2Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16 3CMR Institute Adds e-Modules Addressing Healthcare Reform's Impact on Pharmaceutical Industry 2
(Date:10/30/2014)... Chicago, IL (PRWEB) October 30, 2014 Dr. ... launched a new website for his practices; OB GYN ... Chicago, IL . This website contains important information about ... covers as well as downloadable patient forms in English and ... use and the service pages on the website provide Dr. ...
(Date:10/30/2014)... Newport Beach, California (PRWEB) October 30, 2014 ... superfood nutrtion bars are now available through a unique ... an online site designed to empower the everyday athlete. ... the worlds best athletes and created a system to ... really excited to see REV’D® is now available on ...
(Date:10/30/2014)... October 30, 2014 Sound Telecom, a leader ... that will assist people any time they wonder, “Should I ... right answer by leading them through a series of yes ... their initial query. , There are many considerations and scenarios ... use an answering service . This decision infographic serves ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... milk could be bad for your health, a new study ... milk can help strengthen bones and prevent osteoporosis. These benefits ... milk as part of a healthy diet. But this ... not protect men or women from bone fractures, and was ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- A new vaccine ... meningococcal disease was approved by the U.S. Food and ... protect people between the ages of 10 and 25 ... serogroup B bacteria. The bacteria can infect ... spinal cord and brain. It is a leading cause ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2
... - Month-12 Independent Echocardiographic Data Safety Monitoring ... Safety Profile -, SAN DIEGO, March ... ) announced today that following a planned ... Board (EDSMB) it is,continuing BLOOM (Behavioral modification ...
... now cover Monogram,s Trofile assay, SOUTH SAN ... MGRM ) today announced that the,California Medicaid ... Trofile Assay., Medi-Cal is the state medical ... care and services to individuals,or families on public ...
... supported by the National Institutes of Health (NIH) ... Infectious Diseases (NIAID) has identified chemical compounds that ... parasitic disease that afflicts more than 200 million ... the advance online publication of the journal Nature ...
... can contribute to weight gain, experts say, , , SUNDAY, March ... for some people be as simple as getting some extra ... don,t get enough sleep tend to weigh more -- and ... and ghrelin. , "There is a dynamic balance between ...
... Guidelines Emphasize Importance of Allergy Testing to Control Chronic ... ... 14 Allergy and asthma specialists,from around the country will gather ... (NAEPP) Guidelines for,the Diagnosis and Management of Asthma. These guidelines are ...
... As the state,s leading health,groups working to reduce the ... continued efforts to enforce the Freedom to Breathe,Act by ... by the City of Maplewood are a positive step,toward ... congratulate,their efforts to protect health," said Pat McKone, Director ...
Cached Medicine News:Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 2Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 3Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 4Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 5Health News:Arena Pharmaceuticals' Lorcaserin for Obesity Passes Major Safety Milestone 6Health News:California Medicaid Establishes Coverage for Trofile(TM) 2Health News:California Medicaid Establishes Coverage for Trofile(TM) 3Health News:California Medicaid Establishes Coverage for Trofile(TM) 4Health News:Scientists identify new leads for treating parasitic worm disease 2Health News:Scientists identify new leads for treating parasitic worm disease 3Health News:Starved for Sleep? Watch Your Waistline 2Health News:Starved for Sleep? Watch Your Waistline 3Health News:NIH Asthma Guidelines Will Leave Sufferers Breathing Easier This Spring 2Health News:Leading Health Groups Applaud Continued Efforts to Protect Public Health by Ending So-Called 'Theatrical Productions' in Bars 2
... EBV laboratory diagnosis is generally confirmed by a ... the disease however, is not indicated by the ... in 10 - 20 percent of children. ... necessary to fully ascertain the stage of EBV ...
... Bard® Biopsy Instrument and Needle is specially ... goal: a large quality, reliable core sample. ... featuring ultra-sharp tips and polished surfaces for ... of biopsy systems and needle sizes assures ...
... to bring efficiency and quality to routine ... superior technology of fluorescent flow cytometry with ... sampling or batch processing are easily accommodated ... in high volume laboratories. Fluorescent flow ...
... The IsoSleeve™ Source Delivery System incorporates ... design that provides the confidence that each ... prior to implant. Unlike other preloaded needle ... verification of the loading configuration giving you ...
Medicine Products: